We are live on ! Find out more
IMMU

Immunomedics Inc
IMMU

Delisted

IMMU was delisted on the 22nd of October, 2020.

157 hedge funds and large institutions have $1.99B invested in Immunomedics Inc in 2017 Q4 according to their latest regulatory filings, with 35 funds opening new positions, 58 increasing their positions, 48 reducing their positions, and 28 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more call options, than puts

Call options by funds: $168M | Put options by funds: $84.2M

25% more first-time investments, than exits

New positions opened: 35 | Existing positions closed: 28

23% more capital invested

Capital invested by funds: $1.62B → $1.99B (+$370M)

21% more repeat investments, than reductions

Existing positions increased: 58 | Existing positions reduced: 48

5% more funds holding

Funds holding: 150157 (+7)

10% less funds holding in top 10

Funds holding in top 10: 109 (-1)

Holders
157
Holders Change
+7
Holders Change %
+4.67%
% of All Funds
3.56%
Holding in Top 10
9
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-10%
% of All Funds
0.2%
New
35
Increased
58
Reduced
48
Closed
28
Calls
$168M
Puts
$84.2M
Net Calls
+$84.1M
Net Calls Change
+$43.5M
Name Holding Trade Value Shares
Change
Change in
Stake
OM
26
Opaleye Management
Massachusetts
$14.5M
Franklin Resources
27
Franklin Resources
California
$12.5M +$9.16M +775,800 New
Deutsche Bank
28
Deutsche Bank
Germany
$12.4M -$7.28M -616,502 -44%
Morgan Stanley
29
Morgan Stanley
New York
$11M +$2.83M +240,010 +55%
PAM
30
Panagora Asset Management
Massachusetts
$10.5M +$11.2K +946 +0.1%
Ameriprise
31
Ameriprise
Minnesota
$9.71M +$193K +16,331 +3%
Goldman Sachs
32
Goldman Sachs
New York
$9.39M -$4.02M -340,184 -37%
Bank of New York Mellon
33
Bank of New York Mellon
New York
$9.33M -$1.23M -103,960 -15%
CS
34
Candriam SCA
Luxembourg
$8.97M +$714K +60,500 +12%
Invesco
35
Invesco
Georgia
$8.87M -$902K -76,459 -12%
Charles Schwab
36
Charles Schwab
California
$8.36M +$577K +48,879 +10%
Citigroup
37
Citigroup
New York
$7.92M +$3.38M +286,748 +141%
RPAM
38
Rhenman & Partners Asset Management
Sweden
$7.76M -$232K -19,670 -4%
MWNA
39
Marshall Wace North America
New York
$7.74M +$5.65M +478,812 New
IHM
40
Iguana Healthcare Management
New York
$7.27M -$590K -50,000 -10%
LSC
41
Lyon Street Capital
California
$7.22M +$3.5M +296,703 +198%
Point72 Asset Management
42
Point72 Asset Management
Connecticut
$6.73M +$4.92M +416,532 New
NC
43
Nexthera Capital
New York
$6.54M -$4.57M -387,578 -49%
Susquehanna International Group
44
Susquehanna International Group
Pennsylvania
$6.45M +$3.67M +310,813 +351%
Wells Fargo
45
Wells Fargo
California
$6.29M +$1.11M +94,372 +32%
UBS Group
46
UBS Group
Switzerland
$5.82M +$537K +45,495 +14%
Two Sigma Advisers
47
Two Sigma Advisers
New York
$5.46M +$28.4K +2,405 +0.7%
NIP
48
Nicholas Investment Partners
California
$5.08M -$235K -19,904 -6%
DCM
49
DAFNA Capital Management
California
$4.91M -$1.85M -156,451 -34%
B
50
Bailard
California
$4.48M

IMMU Hedge Fund Activity: Q4 2017 in Review

157 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Immunomedics Inc (IMMU) for Q4 2017, worth a combined $1.99B — up 23% from $1.62B a quarter earlier.

Buyers outnumbered sellers: 35 funds opened new IMMU positions and 28 closed out — a net gain of 7 holders — while 58 added to existing stakes and 48 trimmed.

The largest buyer was Millennium Management, adding an estimated $39.9M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $40M sold.

  • 157 institutional investors held Immunomedics Inc (IMMU) as of Q4 2017, up from 150 in Q3 2017.
  • Funds reported $1.99B of Immunomedics Inc stock for Q4 2017, up 23% quarter-over-quarter.
  • 35 funds opened new Immunomedics Inc positions in Q4 2017 and 28 closed out, a net change of +7 holders.
  • The largest Immunomedics Inc buyer in Q4 2017 was Millennium Management, an estimated $39.9M added.
  • The largest Immunomedics Inc seller in Q4 2017 was EcoR1 Capital, an estimated $40M sold.

Based on aggregated 13F filings for Q4 2017.